Abstract 145P
Background
Perioperative immunotherapy has become a new standard of care in resectable locally advanced NSCLC. However, the optimal neoadjuvant and adjuvant treatment are unknown. Angiogenesis inhibitors have been reported to adjust tumor microenvironment and synergistic effects of immunotherapy. Here, we present updated efficacy and safety data of Penpulimab-based combination neoadjuvant/adjuvant therapy for this population in ALTER-L043.
Methods
Patients (pts) with resectable stage IIB-IIIB (N2) NSCLC, without driver gene mutations, were randomized 1:1:1 to receive one of the three regimens in 21-day cycle: Penpulimab (200mg, iv, day 1) + chemotherapy + Anlotinib (12mg, po, day 1-14) (Arm A) or Penpulimab (200mg, iv, day 1) + chemotherapy (Arm B) or Penpulimab (200mg, iv, day 1) + Anlotinib (12mg, po, day 1-14) (Arm C) for 3-4 cycles before surgery, followed by adjuvant therapy of Penpulimab + Anlotinib (Arm A, C) or Penpulimab monotherapy (Arm B) for a year at most. Primary endpoint was major pathological response (MPR) rate, secondary endpoints were objective response rate (ORR), pathologic complete response (pCR), event-free survival (EFS), 1 year EFS rate, overall survival (OS) and safety.
Results
A total of 90 pts were randomized to Arm A (n=30) or Arm B (n=30) or Arm C (n=30). At data cutoff on Sep 30, 2024, median follow-up was 12.8 months. Definitive surgery rates in Arm A/B/C were 62.5% vs 89.7% vs 70.0% respectively. The MPR rates of intention to treat (ITT) population were 76.0% vs 57.7% vs 52.4% in the three arms, and 52.0% vs 50.0% vs 38.1% pts showed pCR respectively. ORR of neoadjuvant therapy was 77.8% vs 58.6% vs 63.3% in the three arms. The incidence of grade ≥ 3 adverse events (AEs) were 46.7% vs 36.7% vs 13.3% respectively. There is no fatal AE related to Penpulimab or Anlotinib.
Conclusions
The results demonstrated that these new perioperative combinations of ICI and Anti-angiogenesis agent (Penpulimab and Anlotinib) with or without chemotherapy showed promising efficacy and with manageable safety profiles.
Clinical trial identification
NCT04846634.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract